Categories: BrainDiagnosticsNews

Nexstim Plc’s Financial Information in 2023

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Company Announcement, Helsinki, 23 December 2022 at 1 PM (EET)

Nexstim Plc’s Financial Information in 2023

Nexstim Plc (NXTMH:HEX, NXTMS:STO) (“Nexstim” or “Company”) announces that it will publish the following financial information in 2023:

The 2022 Financial Statements Release and Half-Yearly Report July−December 2022 (H2) on Monday, February 27, 2023. Half-Yearly Report January-June 2023 (H1) on Friday, August 11, 2023.

Nexstim’s Annual Report 2022 will be published and available on the Company’s website on Monday, March 6, 2023.

The Annual General Meeting is tentatively scheduled to be held on Friday March 31, 2023 at 10:00 am.

NEXSTIM PLC        

Mikko Karvinen, CEO

Further information is available on the website www.nexstim.com, or by contacting:

Mikko Karvinen, CEO
+358 50 326 4101
mikko.karvinen@nexstim.com

The Company’s Certified Advisor is Erik Penser Bank.

About Nexstim Plc

Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.

Nexstim’s Therapy Business markets and sells the Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.

Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

For more information, please visit www.nexstim.com

Attachment

Staff

Recent Posts

Launch of 60-Count Sleep Gummies into the Middle Eastern Markets Drives Further Growth of Delivra Health Brands’ Dream Water(R) Brand

Vancouver, British Columbia--(Newsfile Corp. - May 8, 2025) - Delivra Health Brands Inc. (TSXV: DHB)…

4 hours ago

Clarium Raises $27M Series A to Scale AI-Powered Supply Chain Resiliency Technology to Leading Health Systems

Amid global supply chain volatility, Yale, Stanford, and Kaiser Permanente build resilient healthcare supply networks…

4 hours ago

Labcorp to Webcast Its Annual Meeting of Shareholders May 15

BURLINGTON, N.C., May 8, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive…

4 hours ago

Waystar Named Top Healthcare Payments Software Platform by MedTech Breakthrough

Recognition underscores the differentiated value of Waystar's software platform in addressing nearly half a trillion…

4 hours ago

Astrana Health, Inc. Reports First Quarter 2025 Results

Company to Host Conference Call on Thursday, May 8, 2025, at 2:30 p.m. PT/5:30 p.m.…

4 hours ago

Nsight Health and Zoo Health Announce Strategic Partnership to Expand Access to Remote Patient Monitoring and Chronic Care Management

MIAMI, May 8, 2025 /PRNewswire/ -- Nsight Health, a leading provider of Remote Patient Monitoring…

4 hours ago